Uncategorized

The projects, which include technology upgrades and expanded capacity initiatives, are designed to meet growing demand for services in the region.

Competing with companies including Stryker and J&J, Zimmer has moved to strengthen its position by developing an updated robot.

The incoming AdvaMed chair talked about updates to Resmed’s products and how the company is handling competitive dynamics and tariffs.

Halda Therapeutics is developing oral assets for prostate and lung cancer. The deal comes after Johnson & Johnson set an ambitious goal for its oncology sales by 2030.

Sarepta must also run a post-marketing study for Elevidys to better assess the risk of serious liver injury in patients dosed with the gene therapy.

The companies have yet to disclose how many programs they plan to collaborate on or what indications they will prioritize.

Signs of Frustration Build Between Kennedy, Makary

Aside from announcing layoffs, Sensei has decided to terminate its R&D work. The biotech has $25 million on hand, and continues to evaluate its strategic alternatives.

Artios Pharma is working on a pipeline of oncology assets, led by alnodesertib, currently being tested for second-line pancreatic cancer and third-line colorectal cancer.

Las neuronas son células altamente especializadas, y su correcto funcionamiento depende de que conserven su identidad a lo largo de toda la vida. Ahora, unos científicos han identificado en ratones un mecanismo que protege la identidad de las neuronas: dos enzimas, unas proteína …